---
title: "Evaxion A/S (EVAX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/EVAX.US.md"
symbol: "EVAX.US"
name: "Evaxion A/S"
industry: "Biotechnology"
datetime: "2026-05-19T19:29:09.214Z"
locales:
  - [en](https://longbridge.com/en/quote/EVAX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/EVAX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/EVAX.US.md)
---

# Evaxion A/S (EVAX.US)

## Company Overview

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [evaxion.ai](https://evaxion.ai) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:13.000Z

**Overall: C (0.52)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 160 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 128.61% |  |
| Net Profit YoY | 26.87% |  |
| P/B Ratio | 2.58 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 34111479.35 |  |
| Revenue | 7528000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -82.93% | E |
| Profit Margin | -129.60% | E |
| Gross Margin | 0.00% | E |
| Revenue YoY | 128.61% | A |
| Net Profit YoY | 26.87% | B |
| Total Assets YoY | -6.33% | D |
| Net Assets YoY | 27.96% | A |
| Cash Flow Margin | 0.00% | D |
| OCF YoY | 128.61% | A |
| Turnover | 0.31 | D |
| Gearing Ratio | 44.14% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Evaxion A/S",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "128.61%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "26.87%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.58",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "34111479.35",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "7528000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-82.93%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-129.60%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "0.00%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "128.61%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "26.87%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-6.33%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "27.96%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "128.61%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.31",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "44.14%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -3.50 | 322/386 | - | - | - |
| PB | 2.58 | 228/386 | 2.99 | 2.11 | 1.65 |
| PS (TTM) | 4.53 | 99/386 | 6.03 | 5.12 | 4.25 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-11T04:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 3 | 75% |
| Overweight | 1 | 25% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 3.96 |
| Highest Target | 16.00 |
| Lowest Target | 9.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/EVAX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/EVAX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/EVAX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/EVAX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**